MedTrace Logo

Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies

NCT00195156 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2006-09-14

No results posted yet for this study

Summary

The purpose of this study is to find out the highest tolerated dose of Depakote in combination with liposome encapsulated all-trans retinoic acid (ATRA-IV) in patients with advanced solid tumor malignancies.

Conditions

  • Solid Tumor Malignancies

Interventions

DRUG

ATRA-IV

DRUG

Depakote

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • David Nanus, M.D. · Weill Medical College of Cornell University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00195156 on ClinicalTrials.gov